<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N81</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-06-19</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of intravenous dexmedetomidine with intravenous dexamethasone in providing analgesia and reducing nausea and vomiting after laparoscopic cholecystectomy.</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effects of intravenous dexmedetomidine infusion with intravenous dexamethasone in providing analgesia and reducing nausea and vomiting after laparoscopic cholecystectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>165</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/88893</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Three drugs are named A, B, and C, and only the third person who gives the drug to the patient knows which drug has which letter, and decoding is done at the end of the study.
People are written from top to bottom based on the national code, and based on a random method, if the number 1 is determined, the first group, that is, three people, enters the ABC group, and the first person A, the second person B, and the third person C.
If the random number 2 comes, the second group in the same way, and if the random number 3 comes, the third group, if the random number 4 comes, group 4, if the random number 5 comes, group 5, and if the random number 6 comes, group 6. If the random numbers 7, 8, and 9 come, it is repeated until one of the random numbers comes up.
We have 55 random blocks of three. For example, if two patients are candidates for surgery today, we assume a third patient and form a block and specify the block. If the third patient comes in the future, his block is already specified and he will receive the desired drug, Blinding description: -The participants are the same patients who have undergone abdominal cholecystectomy surgery and are blinded in this study because the study was explained to them before consent was obtained, but they are not aware of the coding of the groups and the grouping.
-The nursing and operating room staff are also blinded as clinical care because they are not aware of the grouping.
-The researcher is also blinded in this study because he does not personally perform the grouping and drug injection.
-The professor, statistical consultant and student (researcher) are also blinded as data analysts in this study because they only analyze and interpret the collected information.
-The only group that is awake is the nursing staff and the drug injectors who collect the data and are aware of the coding of the groups and the grouping and the intervention that is performed for each patient.</study_design>
      <phase>3</phase>
      <hc_freetext>laparoscopic cholecystectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:The group that received 0.5-1 µg dexmedetomidine as a bolus over ten minutes and a dose of 0.2-0.7 µg/kg/h infusion. Intervention 2: Intervention group: Group receiving 4mg/2ml dexamethasone single dose and 0.1mg/kg normal saline to a final volume of 20cc. Intervention 3: Control group: The group receiving placebo (normal saline).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is no more information availabe.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abolfazl Dehghani Farfani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 4, Shahid Mirzaei Alley, Arisoon St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8159135515</zip>
        <telephone>0098315232492</telephone>
        <email>Abolfazl.Dehghani9820@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazemroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>0098 31 822 2532</telephone>
        <email>Behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient consent to enter the study
The patient is a candidate for laparoscopic cholecystectomy.
American Society of Anesthesiologists (ASA) Class II-I
No prior history of chemotherapy
Age 18 to 60 years
Maximum operation time 150 minutes</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Taking steroids before surgery
Allergy to dexamethasone or dexmedetomidine
being pregnant</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K80</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cholelithiasis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:The group that received 0.5-1 µg dexmedetomidine as a bolus over ten minutes and a dose of 0.2-0.7 µg/kg/h infusion</i_keyword>
      <i_keyword>Intervention group: Group receiving 4mg/2ml dexamethasone single dose and 0.1mg/kg normal saline to a final volume of 20cc</i_keyword>
      <i_keyword>Control group: The group receiving placebo (normal saline).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea. Timepoint: From patient recovery until 4 hours after surgery, every 30 minutes in 3 groups. Method of measurement: Ask the patient.</prim_outcome>
      <prim_outcome>Vomiting. Timepoint: From patient recovery until 4 hours after surgery, every 30 minutes in 3 groups. Method of measurement: Ask the patient.</prim_outcome>
      <prim_outcome>Pain. Timepoint: From patient recovery until 4 hours after surgery, every 30 minutes in 3 groups. Method of measurement: VAS score system.</prim_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: During the procedure after receiving the medication, every 15 minutes until the end of the surgery. Method of measurement: Non invasive blood pressure measurement.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: During the procedure after receiving the medication, every 15 minutes until the end of the surgery. Method of measurement: Non invasive blood pressure measurement.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: During the procedure after receiving the medication, every 15 minutes until the end of the surgery. Method of measurement: ECG Monitoring.</prim_outcome>
      <prim_outcome>Blood oxygen saturation. Timepoint: During the procedure after receiving the medication, every 15 minutes until the end of the surgery. Method of measurement: Pulse oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-20</approval_date>
        <contact_name>Research Ethics Committee of Alzahra Research Centers , Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar jerib Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
